Home » Authors » Jim Stommen

Articles by Jim Stommen

JPMorgan Healthcare Conference: Conor Medsystems, ev3 draw interested investor attendees

Jan. 19, 2006

JPMorgan Healthcare Conference: Spinal firms back up pitches with both market, trial data

Jan. 18, 2006

JPMorgan Healthcare Conference: Lab equipment makers pushing new systems to meet lab needs

Jan. 17, 2006

Market positions buoy pitches by NMT Medical and Thoratec

Jan. 13, 2006

Diag firms attract investor interest as test value grows

Jan. 13, 2006

Patient monitoring and HIT are growth sectors for Medtronic

Jan. 12, 2006

On St. Jude's run of success, Starks says, 'We're not done'

Jan. 12, 2006

'Innovation' is word of the day as orthopedic firms take stage

Jan. 12, 2006

Meat-and-potatoes path takes C.R. Bard to $1.78B in sales

Jan. 11, 2006

Smaller companies attracting big interest from investors

Jan. 11, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 18, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 18, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...